Profile data is unavailable for this security.
About the company
Animalcare Group plc is a United Kingdom-based international veterinary sales and marketing company. The Company is focused on bringing products to market through its own development pipeline, partnerships and through acquisitions. The Company develops and commercializes prescription and over-the-counter pharmaceutical products that improve animal health and wellbeing. These are developed in-house, acquired from other companies or in-licensed from its partners. The Company manages an international supply chain, including specialist veterinary wholesalers and distributors. It partners with companies to commercialize products across Europe. The Company operates in three categories within the veterinary market: companion animals, equine and other, and production animals. Its product pipeline is Daxocox, which is a differentiated COX-2 inhibitor for the treatment of chronic pain in dogs. The Company operates in seven countries and exports to about 40 countries in Europe and worldwide.
- Revenue in GBP (TTM)74.55m
- Net income in GBP4.69m
- Incorporated1972
- Employees226.00
- LocationAnimalcare Group plcMoorside, Monks CrossYORK YO32 9LBUnited KingdomGBR
- Phone+44 190 448 7687
- Fax+44 190 448 7611
- Websitehttps://www.animalcaregroup.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cenra Inc | 218.87m | 9.11m | 138.36m | 1.40k | 25.34 | 0.754 | 7.81 | 0.6322 | 1.50 | 1.50 | 34.28 | 50.26 | 0.7106 | 2.15 | 5.73 | -- | 2.97 | 3.69 | 4.29 | 4.96 | 37.10 | 36.56 | 4.18 | 5.50 | 0.7054 | -- | 0.2976 | 52.77 | 1.40 | 2.50 | -32.51 | -2.72 | 3.57 | -8.97 |
Zota Health Care Ltd | 20.81m | -3.28m | 141.55m | 445.00 | -- | 9.42 | -- | 6.80 | -13.20 | -13.20 | 84.28 | 59.92 | 0.8794 | 2.11 | 7.20 | 4,947,045.00 | -13.89 | -1.38 | -17.57 | -1.85 | 51.96 | 35.95 | -15.79 | -1.33 | 0.8357 | -3.46 | 0.3966 | -- | 28.96 | 16.08 | -148.54 | -- | 39.85 | 0.00 |
Mediwound Ltd | 16.07m | -15.94m | 141.84m | 100.00 | -- | 8.56 | -- | 8.83 | -2.16 | -2.16 | 2.18 | 1.92 | 0.3311 | 5.53 | 6.55 | 201,410.00 | -32.83 | -24.48 | -49.28 | -32.92 | 13.25 | 43.27 | -99.17 | -38.43 | 1.51 | -3.26 | 0.2623 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
LifeVantage Corp | 156.41m | 3.30m | 141.92m | 217.00 | 44.49 | 6.40 | 23.42 | 0.9074 | 0.3192 | 0.3192 | 15.27 | 2.22 | 3.06 | 2.50 | 71.64 | 903,290.30 | 6.46 | 9.95 | 10.17 | 15.55 | 79.21 | 81.45 | 2.11 | 3.08 | 0.9923 | 559.36 | 0.00 | 26.95 | -6.20 | -2.40 | 15.63 | -16.94 | -2.18 | -- |
Formosa Pharmaceuticals Inc | 3.37m | -4.91m | 144.03m | -- | -- | 3.67 | -- | 42.78 | -1.49 | -1.49 | 1.02 | 10.62 | -- | -- | -- | -- | -- | -40.34 | -- | -44.21 | 84.63 | -- | -145.95 | -2,488.28 | -- | -- | 0.0167 | -- | 2,270.49 | -- | 20.75 | -- | -42.98 | -- |
T Man Pharmaceutical PCL | 50.35m | 10.03m | 144.49m | -- | 14.40 | 11.86 | 25.06 | 2.87 | 1.08 | 1.08 | 5.44 | 1.32 | 0.875 | 2.14 | 4.01 | -- | 17.43 | -- | 39.47 | -- | 47.56 | -- | 19.92 | -- | 0.366 | 40.92 | 0.3609 | -- | -2.20 | -- | -8.82 | -- | -- | -- |
Animalcare Group Plc | 74.55m | 4.69m | 148.52m | 226.00 | 31.76 | 1.53 | 11.96 | 1.99 | 0.0775 | 0.3033 | 1.23 | 1.61 | 0.6287 | 2.76 | 5.63 | 329,885.00 | 3.96 | 0.3272 | 4.71 | 0.3866 | 57.82 | 54.92 | 6.30 | 0.5484 | 2.67 | 7.17 | 0.0425 | 599.95 | 3.82 | 0.5138 | -38.98 | -- | -11.79 | 2.59 |
Pyridam Farma Tbk PT | 67.52m | -12.76m | 149.11m | 1.33k | -- | 2.47 | -- | 2.21 | -49.15 | -49.15 | 195.71 | 106.69 | 0.3606 | 2.65 | 3.33 | 1,126,088,000.00 | -6.82 | 6.31 | -10.49 | 8.07 | 27.38 | 42.56 | -18.91 | 8.83 | 0.5175 | -1.14 | 0.764 | -- | -1.87 | 22.89 | -130.96 | -- | 2.93 | -- |
Sigachi Industries Ltd | 41.18m | 6.25m | 151.36m | 991.00 | 28.50 | 3.39 | 20.60 | 3.68 | 1.69 | 1.69 | 11.11 | 14.15 | 0.6266 | 3.01 | 3.27 | 4,396,491.00 | 9.36 | 14.77 | 13.25 | 19.57 | 50.50 | 50.30 | 14.93 | 14.92 | 1.39 | 6.47 | 0.2576 | 1.61 | 32.08 | 25.34 | 31.34 | 24.64 | 70.35 | -- |
Essex Bio-Technology Ltd | 165.94m | 26.95m | 157.03m | 1.46k | 6.00 | 0.7603 | 4.82 | 0.9463 | 0.4499 | 0.4499 | 2.73 | 3.55 | 0.5587 | 2.62 | 2.73 | 1,093,064.00 | 9.07 | 11.20 | 12.10 | 14.73 | 89.78 | 86.01 | 16.24 | 19.77 | 1.61 | -- | 0.1397 | 16.16 | 29.51 | 7.72 | 22.11 | 3.56 | 7.29 | 7.39 |
Holder | Shares | % Held |
---|---|---|
Liontrust Investment Partners LLPas of 21 May 2024 | 7.22m | 11.96% |
Harwood Capital LLPas of 07 Oct 2024 | 6.02m | 9.96% |
Canaccord Genuity Wealth Ltd.as of 29 Feb 2024 | 3.85m | 6.38% |
SEB Investment Management AB (Denmark)as of 31 Oct 2024 | 3.59m | 5.95% |
BGF Investment Management Ltd.as of 29 Feb 2024 | 3.56m | 5.89% |
BlackRock Investment Management (UK) Ltd.as of 24 Jan 2024 | 3.00m | 4.97% |
SEB Investment Management ABas of 29 Feb 2024 | 2.33m | 3.85% |
Unicorn Asset Management Ltd.as of 01 May 2024 | 1.68m | 2.79% |
Skandinaviska Enskilda Banken AB (Denmark)as of 31 Oct 2024 | 1.14m | 1.88% |
Octopus Investments Ltd.as of 01 May 2024 | 875.00k | 1.45% |